WO1993024636A1 - Emploi de la proteine oprf dans l'expression d'oligopeptides a la surface de cellules bacteriennes - Google Patents

Emploi de la proteine oprf dans l'expression d'oligopeptides a la surface de cellules bacteriennes Download PDF

Info

Publication number
WO1993024636A1
WO1993024636A1 PCT/CA1993/000227 CA9300227W WO9324636A1 WO 1993024636 A1 WO1993024636 A1 WO 1993024636A1 CA 9300227 W CA9300227 W CA 9300227W WO 9324636 A1 WO9324636 A1 WO 9324636A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
oprf
protein
outer membrane
cells
Prior art date
Application number
PCT/CA1993/000227
Other languages
English (en)
Inventor
Robert E. W. Hancock
Rebecca Wong
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of WO1993024636A1 publication Critical patent/WO1993024636A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to a recombinant expression system for cell surface presentation of proteins and methods for its preparation and use.
  • the method is exemplified by use of the protein OprF as a recombinant expression system for peptide antigens. Background
  • the basic technology involves insertion of oligonucleotides, encoding peptide epitopes of interest, within the gene sequence for a surface or excreted protein such that the peptide of interest is expressed at the surface of the bacterial cell, often facing the external environment Alternatively, one can append larger polypeptides, usually by fusing specific restriction fragments encoding these polypeptides to the amino terminal-encoding fragment of the gene for the extracellularly taigeted protein.
  • the former method, epitope insertion mutagenesis has been performed with outer membrane proteins LamB and FhoE, and to a limited extent with OmpA and TxaT.
  • Patents related to epitope insertion mutagenesis include W088 ⁇ 1873, EP355737, W089 10697, U.S. 4784952, EP146416 and WO8805464.
  • References relating to the LamB and PhoE systems for epitope effusion mutagenesis include Charbit, et al., Gene (1988) 70:181-189 and Komacker and Pugsley Molecular Microbiology (1990) 3:1101-1109.
  • Vaccine (1990) 8:85-91) that the neighboring sequences of an antigenic peptide are important for maximal immunogenicity (i.e., maximal antibody production).
  • a limitation in epitope fusion mutagenesis in the few cases that it has been performed, has been that one must strictly maintain the sequence of triplet codons (i.e. the reading frame) so that the fused sequences are in the same reading frame. This has limited the application of this method to fusion with epitopes for which the complete DNA sequence is known and even then usually requires considerable manipulation to orient the reading frame of the DNA sequence encoding the peptide epitope with the DNA sequence encoding the outer membrane protein.
  • FMDV foot and mouth disease virus
  • VP1 protein myobacterial hsp65 (T cell epitope), poli ⁇ vinis C3 epitope, hepatitis B preS2A and preS2B peptides, HIV gp120 protein, C. traehmatis MOMP, growth hormone releasing factor, ß-lactamase, Plasmodium falciparum (the malaria parasite), Mycobacterium leprae 65 kDa protein and cholera toxin B-subunit (e.g. Charbit et al., (1988) supra: Agteiberg et al.,
  • Vaccine (1990) 8:438-440; van der Werf et al., (1990) supra have been tested.
  • Several authors have demonstrated the ability of purified proteins with inserted epitopes to elicit a B and/or T cell response.
  • a PhoE-FMDV hybrid was shown to protect guinea pigs against foot and mouth disease; Agterberg et al. (1990) supra, and neutralizing antibody has been elicited using several other hybrids as immunogens.
  • a severe limitation on these systems has been that they have been proven useful only for continuous or linear epitopes (i.e., epitopes involving sequences of amino acids that are contiguous with the primary sequence from the antigenic protein in question).
  • conformational epitopes involving amino acids from several parts of the sequence of the antigenic protein cannot be expressed in epitope insertion experiments, and thus largely have been ignored to date, despite the fact that such conformational epitopes are usually more prevalent than linear epitopes in antigenic proteins.
  • the expression system comprises a plasmid which includes a promoter, which may be constitutive or regulatable, and a DNA sequence encoding at least the amino terminal portion of a P. aeruginosa outer membrane protein OprF. Inserted in the DNA sequence are one or more unique restriction sites for insertion of one or more DNA sequences encoding a protein(s) of interest. These inserted sequences can be known as antigenic peptides or random peptides of four or more amino acids created by utilization of randomized oligonucleotide sequences.
  • a DNA sequence encoding an oligopeptide of interest may be fused to the DNA sequence which encodes at least the amino terminal portion of the outer membrane protein.
  • This sequence can be part of a known DNA sequence or can involve random DNA fragments from a protein of interest.
  • the invention finds use for presentation of proteins such as peptide antigens on the cell surface of gram negative bacteria which then can be used as a live vaccine. Alternatively, or in addition, it can be used for mapping of antigenic epitopes, identifying sequences of amino acids that constitute epitopes that can be used in the diagnosis of disease, or production of specific antibodies against a given peptide sequence.
  • Figure 1 shows a diagram of plasmid pRW3, the plasmid used for linker insertion mutagenesis.
  • Figure 2 shows the complete nucleotide sequence of pRW3.
  • Figure 3 shows a Western immunoblot with anti-OprF monoclonal antibody (mAb) MA7-1 against OprF produced by linker insertion mutants and native OprF.
  • mAb monoclonal antibody
  • Figure 4 shows a colony immunoblot with PF2A, 10 (a monoclonal antibody specific for the PNANPNA repeating epitope of Plasmodium falciparum CSprotein) showing reactivity with colonies expressing an OprF derivative carrying the malarial epitope.
  • PF2A, 10 a monoclonal antibody specific for the PNANPNA repeating epitope of Plasmodium falciparum CSprotein
  • Figure 5 shows a Western blot of whole lysates of E. coli strains containing plasmids pRW302M.2 and pRW309M, respectively, with anti-OprF mAb MA7-1 (left of molecular weight marker) and anti-malarial epitope mAb PF2A.10 (right of molecular weight marker).
  • Figure 6 shows Western blots of whole cell proteins using either (a) an anti-OprF mAb MA7-1, or (b) a polyclonal antibody specific for CEME.
  • Lane 1 is the wild type P. aeruginosa strain H103;
  • Lane 2 is an E. coli strain expressing a truncated form of OprF;
  • Lane 3 is in E. coll strain harboring a clone expressing wild type OprF;
  • Lane 4 is an E. coli expression plasmid pMB-CEMB.
  • FIG. 7 shows examples of indirect immunofluorescent labeling experiments with anti-OprF and anti-malarial epitope mAb's.
  • E. coli strain expressing pRW309M with MA7-1 anti-OprF mAb
  • PF2A.10 anti-malarial epitope
  • Figure 8 shows a map of a pUC4K type plasmid. Shaded area indicates kaiamycin resistance cassette used for linker mutagenesis.
  • Figure 9 shows a diagram of plasmid pMB-CEME, an epitope fusion construct comprising the first 188 amino acids of OprF fused to a peptide construct.
  • An expression system which comprises a DNA sequence encoding at least the amino terminal portion of an outer membrane protein OprF, which sequence contains one or more restriction sites for insertion of a coding sequence for an oligopeptide of interest, and/or may be used for fusion to a coding sequence for an oligopeptide of interest such as a peptide antigen.
  • the expression system also provides for DNA sequences for efficient initiation of transcription (promoter) and translation; DNA sequences for efficient termination of transcription and translation; as well as for efficient processing and transportation of the expressed protein across the outer membrane for presentation at the cell surface.
  • the promoter is one capable of providing expression in gram negative bacteria and may be inducible or regulatable.
  • the coding sequences for the outer membrane proteins are modifications of the coding sequence of the OprF gene from Pseudomonas aeruginosa PAOl. Methods for the preparation and use of the expression system also are provided.
  • OprF can directly stimulate immunologically important lymphocytes and itself has vaccine potential against Pseudomonas aeruginosa infections (Hancock et al., European Journal of Clinical Microbiology (1985) 4:224-228; Oilleland et al., and Immunity (1988) 56:1017-1022 and recombinant OprF from E. coli has been used to protect against Pseudomonas infections (Oilleland et al., Current Microbiology (1992) 24:1-7) leading to the potential for a bipartite vaccine.
  • OprF has been demonstrated to be a B-cell mitogen (Chen et al., Infection and Immunity (1980) 28:178-184; it also can be used as an immunogen with liposomal delivery systems. OprF is amenable to both epitope insertion mutagenesis and epitope fusion mutagenesis. Eleven discrete sites have been isolated at which 12 nucleotides could be inserted (resulting in 4-5 amino acids being inserted into the OprF product) and at least 9 of these sites are exposed to the cell surface and are permissive for insertion of a 14 amino acid sequence containing a malaria repeating epitope PNANPNANPNA (see below).
  • Novel expression systems can include those having the following formula:
  • P represents a DNA sequence which provides for efficient initiation of transcription in a host bacterium; the DNA sequence of OprF gene promoter must be modified to prevent overexpression lethality due to the strength of this promoter, this permits introduction of a foreign promoter which may be regulatable or constitutive.
  • a foreign promoter which may be regulatable or constitutive.
  • the phosphato-regulatable promoter from oprP gene of P. aeruginosa or the constitutive oprD gene promoter may be regulatable or constitutive.
  • N represents the coding sequence for the N-termiiul portion of an outer membrane protein and contains a bacterial leader sequence for processing and translocation.
  • R 1 and/or R 2 represent restriction sites for insertion of up to about 207 nucleotides encoding an oligopeptide of interest; the number of restriction sites is about 1 to 4 at R 1 or R 2 ',
  • X represents the central portion of the outer membrane protein.
  • Novel expression systems also include compositions which have the following formulas:
  • N 1 represents the coding sequence for the N-terminus of outer membranae protein OprF and is characterized as providing for expression of a sufficient amount of a consecutive sequence of amino acids from the N-terminus (about 153 or more amino acids) to permit expressions of a peptide fused at R 1 to be expressed on the surface of the outer membrane protein, as well as providing the coding sequence for a bacterial leader sequence to permit processing and translocation to the outer membrane;
  • C 1 represents either an actual OprF carboxy terminus or a synthetic carboxy terminus having substantially the sequence of a native OprF carboxy terminus;
  • P and R 1 have the meaning as described above under Formula (1).
  • outer membrane proteins are of interest.
  • the actual gene and protein have not been identified, nearly all bacterial species rRNA homology group 1 of the Family Pse ⁇ domonadaceae, and certain related species, possess either a sequence that cross-hybridizes with the OprF gene (Ulistrom, et al. Journal Bacteriol (1991) 173:768-775) or a protein that cross-reacts with OprF-specific monoclonal antibodies (N. Martin, Ph.D. Thesis (1992) University of British Columbia, Canada), unlike the proteins from E. coli that have been used previously for epitope insertion or epitope fusion mutagenesis.
  • OprF OprF
  • ability to accept additional peptides at multiple sites, and predictable sites based on the information presented here activity as a B-cell mitogen; ability to function in several bacterial species; and ability to be used for both epitope insertion and epitope fusion.
  • Proteins that are capable of exhibiting such characteristics are of interest in the subject invention as a source of nucleic acid sequences capable of providing for expression of an oligopeptide of interest on the surface of an outer membrane protein.
  • compositions can be prepared by taking DNA encoding at least the N-terminal portion of an outer membrane protein and creating one or more restriction enzyme sites within the coding sequence where a DNA sequence encoding a heterologous protein can be inserted so as to obtain a fusion protein in which an oligopeptide of interest is inserted into the outer membrane protein sequence.
  • the altered gene can be expressed in a host prokaryotic cell, particularly a bacterial cell, more particularly a gram negative bacterial cell.
  • the techniques used in isolating outer membrane protein genes to obtain the desired sequences are known in the art, including synthesis, isolation from genomic DNA. or combinations thereof.
  • Various techniques for manipulation of genes are well known, and include restriction, digestion, resection, ligation, in vitro mutagenesis, primer repair, employing linkers and adapters, and the like (see Sambrook et al., Molecular Cloning, a Laboratory Manual. Cold Spring Harbor, USA, 1989).
  • the method comprises preparing a genomic library from an organism expressing an outer membrane protein with the desired characteristics. The genome of the donor microorganism is isolated and cleaved by an appropriate restriction enzyme, such as Eco R 1 .
  • the fragments obtained are joined to a vector molecule which has previously been cleaved by a compatible restriction enzyme.
  • a suitable vector is plasmid PLAFR3 which can be cleaved by the restriction endonuclease Eco R 1 .
  • the amino acid sequence of an outer membrane protein also can be used to design a probe to screen a cDNA or a genomic library prepared from mRNA or DNA from cells of interest as donor cells for an outer membrane protein gene.
  • the probes can be considerably shorter than the entire sequence but should be at least 18, preferably at least 21, nucleotides in length. Longer oligonucleotides are also useful, up to the full length of the gene, preferably no more than 500, more preferably no more than 250, nucleotides in length.
  • RNA or DNA probes can be used.
  • the probes are typically labeled in a detectable manner for example with 32 P, 3 H, biotin or avidin) and are incubated with single-stranded DNA or RNA from the organism in which a gene is being sought. Hybridization is detected by means of the label after single-stranded and double-stranded (hybridized) DNA (or DNA/RNA) have been separated (typically using nitrocellulose paper). Hybridization techniques suitable for use with oligonucleotides are well known to those skilled in the art. Although probes are normally used with a detectable label that allows easy Identification, unlabeled
  • oligonucleotides are also useful, both as precursors of labeled probes and for use in methods that provide for direct detection of double-stranded DNA (or DNA/RNA). Accordingly, the term “oligonucleotide probe” refers to both labeled and unlabeled forms. Particularly contemplated is the isolation of genes from organisms that express outer membrane proteins using oligonucleotide probes based on the nucleotide sequences of the OprF gene obtainable from Pseudomonas aeruginosa.
  • nucleotide sequence encoding an outer membrane protein has been identified, as a restriction fragment of chromosomal DNA, it can then be manipulated in a variety of ways to prepare an expression system which has a structure represented by formula (1) above.
  • the constructs comprising the expression system may include functions other than those required for expression, such as replication systems in one or more hosts, e.g. cloning hosts and/or the target host for expression of the protein of interest; one or more markers for selection in one or more hosts, as indicated above; genes which enhance transformation efficiency; or other specialized functions.
  • the construct may be prepared in conventional ways, by isolating genes of interest from an appropriate host, by synthesizing all or a portion of the genes, or combinations thereof.
  • the regulatory signals, the transcriptional and translational initiation and termination regions may be isolated from a natural source, be synthesized, or combinations thereof.
  • the various fragments may be subjected to endonuclease digestion (restriction), ligation, sequencing, in vitro mutagenesis, primer repair, or the like.
  • endonuclease digestion restriction
  • ligation sequencing
  • in vitro mutagenesis primer repair
  • the various fragments may be combined, cloned, isolated and sequenced in accordance with conventional ways. After each manipulation, the DNA fragment or combination of fragments may be inserted into the cloning vector, the vector transformed into a cloning host, e.g. E. coli, the cloning host grown up, lysed, the plasmid isolated and the fragment analyzed by restriction analysis, sequencing, combinations thereof, or the like.
  • a cloning host e.g. E. coli
  • the cloning host grown up, lysed
  • the plasmid isolated analyzed by restriction analysis, sequencing, combinations thereof, or the like.
  • Various vectors may be employed during the course of development of the construct and transformation of the host cell. These vectors may include cloning vectors, expression vectors, and vectors providing for integration into the host or the use of bare DNA for transformation and integration.
  • the cloning vector will be characterized, for the most part, by a marker for selection of t host containing the cloning vector and optionally a transformation stimulating sequence, may have one or more polylinkers, or additional sequences for insertion, selection, manipulation, ease of sequencing, excision, or the like.
  • Expression of an oligopeptide of interest is achieved by insertion of one or more open reading frame(s) encoding an oligopeptide of interest(s) into a restriction site created in the sequence encoding the outer membrane protein. Insertions are made by using a variety of molecular genetic techniques which are well known in the art. The structure of the modified genes can vary significantly depending on the location of the restriction enzyme site into which the sequence encoding the antigen of interest is inserted.
  • oligonucleotides varying in length from about 12 to 24 nucleotides and including every possible nucleotide (ACG or T) at every position along the length of the oligonucleotide can be inserted into the restriction enzyme site of choice; resulting, after transformation of cells with these constructs, in a series of derivatives of every possible combination of amino acid sequence in peptide inserts varying from 4 to 8 amino acids in length to create a Variable Epitope Library.
  • Such regions may be identified by inserting a known epitope (e.g. PNANPNANPNA) for which a monoclonal antibody is available, and examining intact cells producing the outer membrane protein with this known epitope by indirect immunofluorescent techniques using the monoclonal antibody. Positive fluorescence will reveal a surface-localized epitope and consequently a region exposed to the surface that is a permissive site for insertion of epitopes.
  • these regions correspond to a loop region that falls between two transmembrane ⁇ -sheets although such regions are notoriously difficult to predict in outer membrance proteins.
  • an oligonucleotide may be used as need to create a unique site. It is advantageous to create at least two unique restriction sites per plasmid within the outer membrane protein gene to permit the construction of proteins expressing two or more separate peptide epitopes. It is desirable to maintain the signal sequence (secretory leader) of the outer membrane protein upstream from and in reading frame with the outer membrane coding sequence gene. As few as about 7 amino acids from the N-terminus are required so long as the C-terminus is present. Alternatively, the nucleotide sequence encoding the outer membrane protein may be ligated to a DNA sequence encoding an oligopeptide of interest.
  • the signal sequence and at least about 150 to 180 amino acids from the N-terminus of the outer membrane protein. This involves placement by mutagenesis of restriction sites at or after the position in the DNA sequence equivalent to amino acid 150 (See Table 1).
  • Expression vectors will usually provide for insertion of a construct which includes the transcriptional and transcriptional ilnitiation region and termination regions;
  • the construct may lack one or both of the regulatory regions, which will be provided by the expression vector upon insertion of the sequence encoding the protein product.
  • Illustrative transcriptional regulatory regions or promoters include, the lambda left and right promoters, trp and lac promoters, tac promoter, and the like.
  • transcriptional regulatory region may additionally include regulatory sequences which allow the time of expression of the fused gene to be modulated, for example the presence or absence of nutrients or expression products in the growth medium, temperature, etc. How to obtain and use a promoter to obtain a particular level or timing of expression is well known to these skilled in the art. (See for example, Deuschle et al. EMBO Journal (1986) 5:2987-2994; Soldat et al FEMS Microbiology Letters (1987) 42:163-167.
  • the expression cassette can be included within a replication system for episomal maintenance in an appropriate cellular host or can be provided without a replication system, where it can become integrated into the host genome.
  • the DNA can be introduced into the host in accordance with known techniques.
  • Microbial hosts can be employed which can include, for example gram negative bacteria from the Family Enterobactriaceae such as E. coli and those from the family Pseudomonadaceae such as Pseudomonas aeruginosa.
  • the outer membrane protein expression system may have been obtained from a particular bacterial host, it has been determined for OprF that the system can be used with other gram negative bacterial hosts.
  • Heterologous expression of promoters, terminators and secretion signals is a common observation in studies on gene expression in gram negative bacteria. Since outer membrane proteins are highly expressed in their native state, it is desirable to delete their normal promoter to prevent overexpression lethality in high copy number plasmids, and to permit a choice of promoters to be used for expression of the outer membrane protein.
  • Virtually any peptide sequence can be inserted into the outer membrane protein by means of the insertion of synthetic oligonucleotides or natural DNA sequences at specific permissive sites in the outer membrane protein gene. Such permissive sites can be inserted into the protein and identified as described above.
  • a maximum size limit of 69 amino acids 207 nucleotides
  • Table, pRW311M a maximum size limit of 69 amino acids (207 nucleotides) has been observed (Table, pRW311M), although up to 100 amino acids may be tolerated.
  • the amino acids inserted can be the known sequences of linear (continuous) peptide epitopes that comprise the dominant antigenic portion of organisms including but not limited to viruses, fungi and other bacteria, or can include a Variable Epitope Library as described above. Antibodies against a specific organism or peptide sequence can then be utilized to ensure that the antigen in question is expressed in the former case. Alternatively, anusera can be used to select reactive clones from the Variable Epitope Library of clones, and the DNA sequences corresponding to the inserted epitopes in these permissive clones can be determined. This permits Identification of the unknown epitope sequences corresponding to antibody reactivities in the antisera.
  • the DNA sequence to be fused can be fully synthetic, or can be a portion of a gene of interest (for example, an antigenic protein from an organism, which antigenic protein is known to give rise to antibodies that protect against infections) or if no such gene is known, random DNA sequences from the chromosome of a bacteria of interest. These latter two possibilities are termed a "Fragment Library" above and clones containing sequences corresponding to antigens of interest can be identified using specific antibodies. Conditions are employed for transformation which result in a high frequency of transformation, using either natural or induced transformation systems or by
  • transformed host according to the invention can be used as starting strain in strain improvement processes other than DNA mediated transformation.
  • the resulting strains are considered to form part of the invention.
  • the host can be grown to express the altered gene.
  • a regulatable promoter such as a lac promoter
  • expression of the mutated outer membrane protein is controlled by the amount of regulator nutrient in the growth medium.
  • the insertion and/or fusion constructs are transformed into a gram negative bacterium host, preferably P. aeruginosa or E. coli or live vaccine strains of Salmonella or Franclscella, by methods known in the art. Transformants are selected by using a bacterial selection marker such as tetracycline resistance.
  • the structural gene providing the marker for selection or maintenance of the plasmid may be native to the wild-type bacterial host or a heterologous structural gene which is functional in the host.
  • structural genes coding for an enzyme in a metabolic pathway may be used where the structural gene is functional in the host and complements the auxotrophy to prototrophy.
  • Transformants are purified and tested for expression of the antigen of interest. This is done using specific antibodies in a colony immunoblot test after transfer of these colonies to nitrocellulose paper.
  • specific clones of interest will be enriched for by using their ability to bind to specific antibodies bound to either a bead support in columns or to the surface of plastic dishes. Bound clones will be those which express an antigenic sequence corresponding to the antibodies. These clones can be eluted by mild acid or high salt, grown up and subjected to further cycles of enrichment prior to testing by colony immunoblot methods.
  • the DNA sequences of the expression system can be derived from an OprF gene, which encodes outer membrane protein, isolated from the gram negative bacterium P. aeruginosa in which organism (as indeed it is in E. coli) it is expressed and efficiently translocated to the outer membrane.
  • the cloned outer membrane protein of P. aeruginosa can also be used to create mutant outer membrane protein genes with improved expression and/or secretion characteristics by using molecular genetic techniques well known in the art.
  • hybrid sequences for expression and secretion of proteins can be obtained by combining outer membrane protein secretion signal sequences with other promoter or terminator sequences.
  • Outer membrane protein gene promoter, secretion signal and optionally terminator sequences, or functional parts thereof, can be obtained and used as individual cassettes in complete expression systems.
  • the invention includes genes with different nucleotide sequences which are homologies of the outer membrane protein gene of P. aeruginosa or parts thereof.
  • Homolog genes may be isolated from natural sources, or may be produced by
  • the subject invention exemplifies a method to efficiently express peptide antigens in a gram negative bacterium such as P. aeruginosa, and E. coli using regulatory sequences obtainable from an outer membrane protein.
  • the invention provides conservative mutations, where the sequence may have as many as 30% different bases, more usually not more than about 10% different bases, or mutations which are non-conservative.
  • the isolation of the outer membrane protein gene allows use of the regulatory elements of the outer membrane protein gene, such as a promoter, an upstream activating sequence (UAS), a terminator and the like, for identification of other specific regulatory sequences by means of standard techniques such as gel retardation, cross-linking, DNA footprinting and the like. Isolation of specific regulatory protein by affinity chromatography will result in the cloning of the gene encoding said protein and subsequent manipulation in a suitable host.
  • a promoter such as a promoter, an upstream activating sequence (UAS), a terminator and the like
  • the uses of these expression systems include the potential for expressing antigenic peptides of interest in live vaccine strains of bacteria.
  • the antigenic peptide would comprise a sequence that could give rise to an immune response leading to antibodies or activated T cells capable of protecting against subsequent infection by a pathogenic organism which includes this antigenic peptide on its surface.
  • the advantage of this invention for such purposes include (a) the ability to express the antigenic peptide at the surface of the live vaccine strain by incorporation into the outer surface of the outer membrane protein, which itself is expressed on the surface of the bacterial cell, (b) the known vaccine potential of OprF against P.
  • a second use is to prepare a protein vaccine by purification using standard detergent solubilization and column chromatography techniques of the protein expressing an antigenic peptide, as described above.
  • OprF being capable of being inserted into liposomes (Hancock et al., European Journal of Clinical Microbiology (1985) 4:224-228) could be delivered in such a formulation as a vaccine.
  • all of the advantages (a) to (e) above would be apparent.
  • a third use is to prepare antibodies against a given peptide sequence.
  • the peptide could be inserted into the outer membrane protein gene as a complementary oligonucleotide.
  • the protein product is then purified and used for immunization of animals.
  • Antibodies so raised that are specific for OprF sequences can be absorbed out using OprF bound to an affinity column matrix.
  • the resultant antibodies are peptide specific.
  • OprF Another advantage of OprF is that since two of the insertion sites exist within a region of OprF that forms one or two disulfide bridges between cysteine residues, the insert at these sites of antigenic peptides that must form disulfide loops for antigenicity, becomes a potential usage of this system.
  • a fourth use of this system is for the identification of important antigenic protein sequences for use as diagnostics or vaccines.
  • This involves creation of a Variable Epitope Library or Fragment Library followed by selection of relevant clones using an anti-sera that is capable of identifying (i.e. diagnosing) all strains of a given species of organism, or an antisera that can protect against infection by the organism. Sequencing of the relevant clones will reveal antigenic epitopes of interest. These can then be used directly (i.e. by use of the original OprF with the inserted peptide) or indirectly (i.e. by using this information to synthesize peptides) for diagnostic tests or as vaccines.
  • the approach utilized to isolate the plasmid pRW3 for creation of OprF epitope insertion vectors was as follows.
  • the OprF gene promoter was mutated by site directed mutagenesis to place a unique HindIII site overlapping the -10 site of the promoter. This had three effects. First, it weakened the promoter. This was important to permit subcloning into high copy number vectors since OprF is such a highly expressed protein (10 5 copies per cell) in both P. aeruginosa and E. coli. Second, it permitted subcloning behind regulated promoters.
  • the promoter-mutated gene was subcloned into plasmids pTZ19R for expression in E. coli or PUCP19 for expression in P.
  • the plasmid pRW3 ( Figure 1), which contains the whole OprF gene with a mutated promoter in pTZ19R, was linearized with 4 different restriction enzymes (Alul, Haeill, Rsal and Thai) which leave blunt ends after digestion. Since all 4 enzymes recognized more than 1 site in the plasmid, different partial digestion conditions were set up for each enzyme in order to obtain the singly cut linearized form of pRW3. After partial digestions, the reaction mixtures were loaded on preoperative agarose gel and the linear form of the plasmid was isolated using DEAE paper.
  • Plasmid DNA from the OprF-minus colonies was extracted by the alkaline lysis method.
  • the extracted plasmid DNA from each OprF-minus clone was then digested with Pstl , which only recognized sites in the flanking sequence of the kanamycin resistance cassette ( Figure 8), and hence cleaved the cassette out from the plasmid.
  • Pstl which only recognized sites in the flanking sequence of the kanamycin resistance cassette
  • cells were plated in ampicillin medium. Colonies that appeared were screened for kanamycin sensitivity and recovery of production of irnmunoreactive OprF.
  • the kanamycin sensitive clones presumably contained the mutated forms of pRW3 with a 12 nucleotide insertion at sites originally interrupted by the kanamycin resistance cassette.
  • Plasmid DNA was prepared from the kanamycin sensitive clones and the insertion sites were mapped by restriction pattern analysis by double digestion with Pstl, which recognized the unique site generated by the 12 nucleotide linker, and other enzymes with single cleavage sites in the oprF sequence. Clones with the same restriction pattern were grouped and 1 clone from each group was further analyzed by automated DNA sequencing using dyeterminator chemistry. For clone 307, a slightly different technique was used.
  • the unique SalI restriction site centered around the sequence encoding amino acid 188 was opened with SalI and a linker sequence with SalI overlapping ends and 12 extra nucleotides containing a PstI site (thus replacing valine 188 with the sequence, gly-pro-alagly-pro) was inserted into this site. In all, 11 unique insertion sites were identified. The 12 nucleotide insertions were translated to 4 amino acids, the identities of which depended on the reading frame at which the insertions occurred (Table 1).
  • Outer membrane samples were prepared from E, coli strains containing different mutated forms of pRW3. Samples were electrophoresed on SDS polyacrylamide gel and analyzed by Western blots using a series of 10 monoclonal antibodies specific for native OprF (Figure 3). Certain of the mutated forms of OprF showed different reactivity patterns with these monoclonal antibodies as compared to the native protein, indicating that certain epitopes were interrupted in these mutated proteins (Table 1). However, reactivity of the mutated proteins with the majority of the monoclonal antibodies indicated substantial retention of native OprF structure.
  • Synthetic oligonucleotides encoding the malaria circumsporozoite (CS) protein repeating sequence PNANPNANPNA were inserted into nine of the mutated forms of pRW3 at the unique PstI site generated by the 12 nucleotide linker (Table 1).
  • the recombinants were screened on colony immunoblots with 2 different monoclonal antibodies specific for the inserted sequence ( Figure 4) as well as with OprF-specific monoclonal antibodies to demonstrate retention of OprF (Table 2).
  • Plasmid DNAs from the positive clones were extracted and digested with Sphl, which recognized a unique site generated by the epitope-specifying sequence. The cleavage of the plasmid DNA by Sphl thus further confirrned the presence of the malarial sequence in the mutated pRW3 derivative plasmids.
  • the surface exposure of the malarial epitope was detected by indirect immunofluorescent labelling.
  • Cells expressing the recombinant OprF with inserted malaria epitopes (Table 3) were incubated with a 100 fold dilution of monoclonal antibody specific for the malarial epitope. After washing with PBS, cells were incubated with a 20 fold dilution of fiuorescein isothiocyanate-conjugated goat anti-mouse IgG. The treated cells were examined under a Zeiss microscope fitted with a condenser for fluorescence microscopy and containing a halogen lamp and suitable filters for emission of fiuorescein isothiocyanate at 525nm ( Figure 7). The retention for surface-localized OprF epitopes was demonstrated in similar indirect immunofluorescent labelling using OprF specific monoclonal antibodies.
  • This oligonucleotide (Table 3, pMB-CEME) encoded an in-frame factor X protease cleavage site followed by a methionine followed by the sequence for a 26 amino acid bacteriocidal protein construct called CEME (a hybrid of insect cecropin and be venom melitin ) and translational stop sites in all three reading frames (i.e. creating a new construct according to formulas (2) and (3)).
  • Expression of this construct ( Figure 9) (containing 41 new C-terminai animo acids fused to OprF) was demonstrated by immunoblotting of whole cell proteins using both a monoclonal antibody specific for the amino terminus of OprF (MA7-1) and a polyclonal antibody specific for CEME ( Figure 6).
  • the factor X cleavage site and the methionine permit potential relief of the peptide by enzymatic or chemical means.
  • the sequence shown in Table 3 (plasmids PAS1 and PAS2) was inserted into the Sal1 site of the oprF gene, This permits blunt-end ligation in all three reading frames of the oprF gene (each using a separate restriction enzyme) to ensure, in one of the three cases, the alignment of the reading frame of any DNA fragment cloned into the sites.
  • the source of these DNA fragments could include genes of interest randomly cut with deoxyribonuclease 1 in the presence of Mn 2 + or by sonication (or when no genes of interest are known, randomly cut chromosomal DNA).
  • the invention described here is a process by which antigenic regions
  • the main component of this invention is a series of 11 plasmids (Fig, 1, Table 1) each containing an engineered cloned oprF gene for the Pseudomonas aeruginosa major outer membrane protein OprF into which has been inserted a 12 nucleotide linker region at a different site of the OprF gene for each of the 11 plasmids (Table 1). Insertion of the 4 extra amino acids encoded by these linkers still permit production of OprF in E, coli (Fig.
  • Results with insertions into this Sall site show that this site can also be utilized for insertion of epitopes giving 10 of the plasmids the potential for simultaneous insertion of 2 epitopes. Furthermore this Sall site has been demonstrated to be capable of acting as a receptor site for fusion of a DNA sequence encoding at least 41 amino acids to the region coding for the first 188 amino acids of OprF. The data further show that OprF can be expressed in both P. aeruginosa and E. coli, giving this system great potential in live vaccine therapy.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouvelles compositions ainsi que leur procédé de préparation et d'utilisation, comprenant une séquence codante pour au moins la partie amino terminale d'une protéine de membrane extérieure dans laquelle le ou les sites enzymatiques de restriction on été insérés pour permettre la liaison d'une séquence codante pour un antigène peptidique, et/ou à laquelle peut être fusionée une telle séquence codante pour un antigène peptidique. On peut synthétiser ou préparer les compositions par génie génétique. Lesdites compositions trouvent une utilisation comme système d'expression dans la préparation de vaccins, et comme technique d'identification de peptides utiles dans le diagnostic de pathologies.
PCT/CA1993/000227 1992-05-29 1993-05-27 Emploi de la proteine oprf dans l'expression d'oligopeptides a la surface de cellules bacteriennes WO1993024636A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89149592A 1992-05-29 1992-05-29
US07/891,495 1992-05-29

Publications (1)

Publication Number Publication Date
WO1993024636A1 true WO1993024636A1 (fr) 1993-12-09

Family

ID=25398288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1993/000227 WO1993024636A1 (fr) 1992-05-29 1993-05-27 Emploi de la proteine oprf dans l'expression d'oligopeptides a la surface de cellules bacteriennes

Country Status (1)

Country Link
WO (1) WO1993024636A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717106A1 (fr) * 1994-12-16 1996-06-19 BEHRINGWERKE Aktiengesellschaft Protéine immunogène hybride OprF-Oprl issue de protéines membranaires de Pseudomonas aeruginosa
JP2006502732A (ja) * 2002-10-17 2006-01-26 バイオリーダーズ コーポレイション ヒト・パピローマウイルスに対するワクチン用ベクターおよび同ベクターによって形質転換された微生物
US7029684B1 (en) * 1997-01-24 2006-04-18 Allan William Cripps Antigenic composition of a Pseudomonas aeruginosa
US7060462B2 (en) * 2000-11-02 2006-06-13 National University Of Singapore AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
US7553636B2 (en) 2001-08-10 2009-06-30 Bioleaders Corporation Surface expression vectors having pgsBCA the gene coding poly-gamma-glutamate synthetase, and a method for expression of target protein at the surface of microorganism using the vector
US7989162B2 (en) 2002-02-07 2011-08-02 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US8367317B2 (en) 2005-04-08 2013-02-05 Melbourne Health; St. Vincent's Hospital Melbourne; Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
EP2650304A1 (fr) * 2010-12-06 2013-10-16 Korea Advanced Institute Of Science And Technology Copolymère multi-bloc peptidique antimicrobien s'exprimant sur la surface des cellules
US8592143B2 (en) 2002-04-12 2013-11-26 Abl Sa Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
WO2020004877A1 (fr) 2018-06-26 2020-01-02 주식회사 바이오리더스 Vecteur d'expression de surface utilisant un gène synthétique de poly-gamma-glutamate dérivé d'une souche dans bacillus, et procédé d'expression de protéine sur la surface d'un micro-organisme l'utilisant
WO2020076078A1 (fr) 2018-10-10 2020-04-16 주식회사 바이오리더스 Vecteur d'expression de surface pour expression élevée constitutive à l'aide d'un promoteur de gène de galactose mutarotase dérivé de lactobacillus casei, et son utilisation
WO2021013904A1 (fr) * 2019-07-23 2021-01-28 Université Grenoble Alpes Anticorps dirigé contre la protéine oprf de pseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146416A1 (fr) * 1983-09-06 1985-06-26 Institut Pasteur Vecteur modifié par une partie au moins, sinon la totalité, du gène lam B et micro-organismes transformés par ce vecteur, et rendus aptes à synthétiser une protéine de membrane externe déterminée, codée par un insérat également contenu dans ledit vecteur
WO1988005464A1 (fr) * 1987-01-20 1988-07-28 Rijksuniversiteit Utrecht PROTEINE DITE PhoE AVEC DETERMINANT ANTIGENIQUE INCORPORE
EP0297291A2 (fr) * 1987-06-03 1989-01-04 BEHRINGWERKE Aktiengesellschaft Protéine de la membrane extérieure F de Pseudomonas aeruginosa
EP0355737A2 (fr) * 1988-08-24 1990-02-28 BEHRINGWERKE Aktiengesellschaft Expression de protéines fonctionnelles homologues et hétérologues sur la membrane extérieure de E.coli et autres bactéries gramnégatives
WO1990011771A1 (fr) * 1989-04-12 1990-10-18 The Rockefeller University Peptides antibacteriens et antipaludeens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146416A1 (fr) * 1983-09-06 1985-06-26 Institut Pasteur Vecteur modifié par une partie au moins, sinon la totalité, du gène lam B et micro-organismes transformés par ce vecteur, et rendus aptes à synthétiser une protéine de membrane externe déterminée, codée par un insérat également contenu dans ledit vecteur
WO1988005464A1 (fr) * 1987-01-20 1988-07-28 Rijksuniversiteit Utrecht PROTEINE DITE PhoE AVEC DETERMINANT ANTIGENIQUE INCORPORE
EP0297291A2 (fr) * 1987-06-03 1989-01-04 BEHRINGWERKE Aktiengesellschaft Protéine de la membrane extérieure F de Pseudomonas aeruginosa
EP0355737A2 (fr) * 1988-08-24 1990-02-28 BEHRINGWERKE Aktiengesellschaft Expression de protéines fonctionnelles homologues et hétérologues sur la membrane extérieure de E.coli et autres bactéries gramnégatives
WO1990011771A1 (fr) * 1989-04-12 1990-10-18 The Rockefeller University Peptides antibacteriens et antipaludeens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY vol. 6, no. 9, September 1988, NEW YORK US pages 1065 - 1070 RUTGERS, T. ET AL. 'Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum' *
CURRENT MICROBIOLOGY vol. 24, no. 1, January 1992, NEW YORK, USA pages 1 - 7 GILLELAND, H. ET AL. 'Recombinant outer membrane protein F of Pseudomonas aeruginosa elicits antibodies that mediate opsonophagocytic killing, but not complement-mediated bacteriolysis, of various strains of P.aeruginosa' cited in the application *
METHODS IN CELL BIOLOGY vol. 34, 1991, pages 77 - 105 HOFNUNG, M. 'Expression of foreign polypeptides at the Escherichia coli cell surface' cited in the application *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955090A (en) * 1994-12-16 1999-09-21 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-OprI derived from Pseudomonas aeruginosa membrane proteins
US6300102B1 (en) 1994-12-16 2001-10-09 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
EP0717106A1 (fr) * 1994-12-16 1996-06-19 BEHRINGWERKE Aktiengesellschaft Protéine immunogène hybride OprF-Oprl issue de protéines membranaires de Pseudomonas aeruginosa
US7029684B1 (en) * 1997-01-24 2006-04-18 Allan William Cripps Antigenic composition of a Pseudomonas aeruginosa
US7371394B2 (en) 1997-01-24 2008-05-13 Auspharm International Limited Antigenic composition of a Pseudomonas aeruginosa protein
US7060462B2 (en) * 2000-11-02 2006-06-13 National University Of Singapore AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
US7553636B2 (en) 2001-08-10 2009-06-30 Bioleaders Corporation Surface expression vectors having pgsBCA the gene coding poly-gamma-glutamate synthetase, and a method for expression of target protein at the surface of microorganism using the vector
US7989162B2 (en) 2002-02-07 2011-08-02 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
US8211633B2 (en) 2002-02-07 2012-07-03 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
US8592143B2 (en) 2002-04-12 2013-11-26 Abl Sa Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
US9702005B2 (en) 2002-04-12 2017-07-11 Abl Sa Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
JP2006502732A (ja) * 2002-10-17 2006-01-26 バイオリーダーズ コーポレイション ヒト・パピローマウイルスに対するワクチン用ベクターおよび同ベクターによって形質転換された微生物
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US8367317B2 (en) 2005-04-08 2013-02-05 Melbourne Health; St. Vincent's Hospital Melbourne; Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US9701982B2 (en) 2005-04-08 2017-07-11 Abl Sa Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
EP2650304A1 (fr) * 2010-12-06 2013-10-16 Korea Advanced Institute Of Science And Technology Copolymère multi-bloc peptidique antimicrobien s'exprimant sur la surface des cellules
JP2014502164A (ja) * 2010-12-06 2014-01-30 コリア アドバンスト インスティテュート オブ サイエンス アンド テクノロジー 細胞表面で発現される抗菌ペプチド多重合複合体
EP2650304A4 (fr) * 2010-12-06 2014-05-21 Korea Advanced Inst Sci & Tech Copolymère multi-bloc peptidique antimicrobien s'exprimant sur la surface des cellules
US10406204B2 (en) 2010-12-06 2019-09-10 Korea Advanced Institute Of Science And Technology Multimeric antimicrobial peptide complex which is displayed on cell surface
WO2020004877A1 (fr) 2018-06-26 2020-01-02 주식회사 바이오리더스 Vecteur d'expression de surface utilisant un gène synthétique de poly-gamma-glutamate dérivé d'une souche dans bacillus, et procédé d'expression de protéine sur la surface d'un micro-organisme l'utilisant
WO2020076078A1 (fr) 2018-10-10 2020-04-16 주식회사 바이오리더스 Vecteur d'expression de surface pour expression élevée constitutive à l'aide d'un promoteur de gène de galactose mutarotase dérivé de lactobacillus casei, et son utilisation
WO2021013904A1 (fr) * 2019-07-23 2021-01-28 Université Grenoble Alpes Anticorps dirigé contre la protéine oprf de pseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
FR3099160A1 (fr) * 2019-07-23 2021-01-29 Université Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant

Similar Documents

Publication Publication Date Title
Charbit et al. Probing the topology of a bacterial membrane protein by genetic insertion of a foreign epitope; expression at the cell surface.
Buysse et al. Molecular cloning of invasion plasmid antigen (ipa) genes from Shigella flexneri: analysis of ipa gene products and genetic mapping
EP1066375B1 (fr) $i(LACTOBACILLUS) HEBERGEANT DES GENES D'AGREGATION CELLULAIRE ET DE FIXATION DE MUCINE, EN TANT QUE VEHICULES D'APPORT DE VACCINS
Anderson et al. Cloning and expression in Escherichia coli of the gene encoding the structural subunit of Bacteroides nodosus fimbriae
CA2123676A1 (fr) Expression de proteines a la surface de bacteries
JPS61274687A (ja) 豚ミコプラスマの組換表面抗原およびワクチン並びにそれらに基づく診断法
JPH06233693A (ja) 連鎖球菌ｍ蛋白免疫原
WO1993024636A1 (fr) Emploi de la proteine oprf dans l'expression d'oligopeptides a la surface de cellules bacteriennes
JP2004337170A (ja) ヘリコバクター感染に対する免疫原性組成物、該組成物に用いられるポリぺプチドおよび該ポリぺプチドをコードする核酸配列
Thiry et al. Cloning of DNA sequences encoding foreign peptides and their expression in the K88 pili
EP0294469B1 (fr) Vaccins et analyses diagnostiques pour l'haemophilus influenzae
JPH0866198A (ja) 肺炎球菌の表面タンパクａのエピトープ領域
US4818694A (en) Production of herpes simplex viral protein
US5356797A (en) Membrane expression of heterologous genes
EP0040922A1 (fr) Séquences d'ADN, molécules d'ADN recombinant et procédé pour la production de polypeptides à spécificité d'antigènes viraux de la fièvre aphteuse
AU714389B2 (en) Export systems for recombinant proteins
Bakker et al. K88 fimbriae as carriers of heterologous antigenic determinants
Dallas et al. Identification and purification of a recombinant Treponema pallidum basic membrane protein antigen expressed in Escherichia coli
TWI241407B (en) Live attenuated bacteria of the species actinobacillus pleuropneumoniae
EP0432220B1 (fr) Vaccins contre l'hemophilus influenzae et analyses permettant de le diagnostiquer
Steidler et al. LamB as a carrier molecule for the functional exposition of IgG-binding domains of the Staphylococcus aureus protein A at the surface of Escherichia coli K12
AU3919993A (en) Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
EP0792365A1 (fr) Immunogenes pour stimuler l'immunite des muqueuses
WO1996011708A1 (fr) Expression membranaire de genes heterologues
US20040076976A1 (en) Aopb gene, protein,homologs, fragments and variants thereof, and their use for cell surface display

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA

NENP Non-entry into the national phase

Ref country code: CA